Gene · 9235
IL32: interleukin 32
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. IL32: interleukin 32. Genes, record 9235. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9235
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P24001 | Interleukin-32 | 234 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents120
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2025172069 A | 2025-11-20 | 20 | P24001 | Espacenet |
| JP 2025172069 A | 2025-11-20 | 24 | P24001 | Espacenet |
| JP 2025172069 A | 2025-11-20 | 26 | P24001 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11426 | P24001 | Espacenet |
| US 12473363 B2 | 2025-11-18 | 927 | P24001 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7063 | P24001 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7064 | P24001 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 7065 | P24001 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 6734 | P24001 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 6734 | P24001 | Espacenet |
1 to 10 of 120
See all 120 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,653
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IL32 papers | Newest fiscal year |
|---|---|---|---|
| R01AI015614 | Pathogenesis of Fever in Man | 26 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 14 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 12 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 10 | 2025 |
| R01AG054324 | Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection. | 9 | 2025 |
| R01AR040312 | CD1-restricted T-cell Responses in Skin | 9 | 2025 |
| P30AR075043 | University of Michigan Skin Biology and Diseases Resource-based Center | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 7 | 2025 |
| R01AI022553 | Molecular Analysis of Host Immune Response in Leprosy | 7 | 2025 |
| P30ES013508 | Center of Excellence in Environmental Toxicology | 5 | 2025 |
1 to 10 of 1,653Source NIH's project files
See all 1,653 nih grantsPapers3,054
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Advanced-stage cutaneous T-cell lymphomas show distinct immune profiles in erythroderma vs. tumor lesions. | J Dermatol Sci | 2026 | 42810908 | PubTator, text mining | PubMed |
| Mitochondrial DNA Released by Biliary Epithelial Cells Enhances Inflammation in Biliary Atresia Through the Cyclic GMP-AMP Synthase-Stimulator of Interferon Genes-Nuclear Factor-κB Pathway. | Cell Mol Gastroenterol Hepatol | 2026 | 42785431 | PubTator, text mining | PubMed |
| IL-32 drives PR3-dependent NET formation to promote portal vein tumor thrombosis and radioresistance in HCC. | Transl Oncol | 2026 | 42767097 | PubTator, text mining | PubMed |
| A Shared EGR1-IL-32-Macrophage Polarisation Signature in Rheumatoid Arthritis and Metabolic Dysfunction-Associated Steatotic Liver Disease. | J Inflamm Res | 2026 | 42703413 | PubTator, text mining | PubMed |
| Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies. | Blood | 2026 | 42685004 | PubTator, text mining | PubMed |
| Dynamic integration of CXCL8 or CCL20 signaling with IL-15 or IL-32α reprograms human T-cell functional plasticity. | Front Immunol | 2026 | 42682451 | PubTator, text mining | PubMed |
| BRD4 contributes to the cytokine-induced acquisition of an IL-13RA2-positive inflammatory fibroblast phenotype. | J Crohns Colitis | 2026 | 42635600 | PubTator, text mining | PubMed |
| Stage-Specific Reduction of Serum IL-32 in Secondary Syphilis and Associations with Lipid Metabolism Parameters. | Diagn Microbiol Infect Dis | 2026 | 42632155 | PubTator, text mining | PubMed |
| Serum IL-32γ as a biomarker for remission assessment in systemic lupus erythematosus. | Front Immunol | 2026 | 42620248 | PubTator, text mining | PubMed |
| Single-cell profiling reveals IFI44L as a central regulator of immune dysregulation in high HIV viral load. | Med Microbiol Immunol | 2026 | 42606736 | PubTator, text mining | PubMed |
1 to 10 of 3,054
See all 3,054 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9235
GET https://conductscience.org/api/genes/v1/9235/patents?page=2